Skip to main content
Fig. 2 | Cancer Imaging

Fig. 2

From: How we read pediatric PET/CT: indications and strategies for image acquisition, interpretation and reporting

Fig. 2

PET response to targeted experimental Phase 1 therapy: Crizotinib in ALK+ IMFT. 18F-FDG-PET and CT imaging of Crizotinib response in IMFT: Baseline whole body 18F-FDG-PET and Chest CT show multiple FDG-avid pulmonary nodules, confirmed by biopsy to be IMFT. Following 1 cycle of therapy, no residual abnormal FDG accumulation is seen (metabolic CR). The lesions have decreased significantly in size by CT, meeting criteria for partial reponse (PR), but not CR. This patient has remained free of disease for >36 months [32].

Back to article page

Cancer Imaging

ISSN: 1470-7330

Contact us